Steffanie A. Strathdee

Steffanie A. Strathdee (born May 28, 1966) is the Associate Dean of Global Health Sciences, Harold Simon Professor at the University of California San Diego School of Medicine and Co-Director at the Center for Innovative Phage Applications and Therapeutics.[1] She has been awarded more than US$64 million in federal research grants as a principal investigator.[2] She is known for her work on HIV research and prevention programmes in Tijuana.[3]

Steffanie A. Strathdee
Strathdee in 2017
Born (1966-05-28) May 28, 1966
Nationality
  • Canadian
  • American
Alma materUniversity of Toronto
Scientific career
FieldsInfectious disease epidemiology
InstitutionsUniversity of California, San Diego
Johns Hopkins University

Strathdee was named one of the 50 Most Influential People in Health Care for 2018 by TIME magazine[4]

Career

Early career

Strathdee is a Canadian-born infectious disease epidemiologist who has spent most of her career focusing on HIV prevention research in underserved, marginalized populations in developed and developing countries, including injection drug users, men having sex with men, and sex workers. Her early research in Vancouver, Canada identified a major outbreak of HIV infection that occurred among injection drug users that occurred despite the presence of one of the largest needle exchange programs in North America. She and her colleagues used this research to successfully advocate for additional HIV prevention and treatment services in Vancouver from the provincial and federal governments. In Vancouver, she founded the Vancouver Injection Drug Use study in 1996, and the Vanguard study of young men who have sex with men. Her work on these studies led her to identify social determinants as independent predictors of HIV risk taking. She received a Young Investigator's Award from the International AIDS Society in 1996 for this research. In 1998, she published a manuscript in JAMA which showed that only half of medically eligible HIV-infected drug users were receiving antiretroviral therapy in Vancouver, which subsequently led to intensified efforts to expand access to HIV care. She was recruited to Johns Hopkins Bloomberg School of Public Health in 1998, where she was an Associate Professor until 2003, before being recruited to the University of California San Diego in 2004.[5]

Leadership in global health

Since 2008, Strathdee has been Associate Dean of Global Health Sciences with responsibility for oversight of UC San Diego's campus-wide Global Health Institute (GHI),[6] which aims to facilitate research, education, private partnerships across diverse disciplines and to address global health challenges in the 21st century. Together with her husband, Dr. Thomas Patterson, she has led a large research and training program on the Mexico-US border. She was chief of the Division of Global Public Health in UC San Diego's Department of Medicine until 2017.[7]

Role in promoting phage therapy

In 2016, Strathdee enlisted the help of an international team of physicians and researchers to save her husband's life with bacteriophage (phage) therapy after he acquired a life-threatening infection with a 'superbug', Acinetobacter baumannii. Although phage therapy had been used for one hundred years in Eastern Europe, it was not licensed for clinical use in the United States or most of Western Europe. Her husband, Dr. Tom Patterson, appears to be the first person in the U.S. to be successfully cured from a systemic multi-drug-resistant bacterial infection with cocktails of intravenous bacteriophages. After the case was published,[8] it received considerable attention in top medical journals including JAMA and Lancet,[9] as well as numerous reports in the international press and a TEDx talk. The Guardian listed this case as one of the top science stories of 2017.[10] Since her husband's release from hospital in 2016, Strathdee and her physician friend, Dr. Robert "Chip" Schooley, who was responsible for treating her husband, have been actively involved in helping other patients receive phage therapy[11] and have launched the Center for Innovative Phage Applications and Therapeutics (IPATH), the first phage therapy center in North America at UCSD which is assisting patients with life-threatening superbug infections obtain treatment. IPATH's goal is to conduct translational research and rigorous clinical trials to determine if phage therapy is efficacious to enable its licensure and widespread use. Dr. Patterson made a full recovery and returned to work in April 2017. Strathdee and her husband have written a book about their story called The Perfect Predator: A Scientists's Race to Save Her Husband from a Deadly Superbug, which was published by Hachette Book Group in 2019.[12] As a result of the Patterson case, dozens other patients with multidrug resistant bacterial infections have been treated with intravenous phage therapy with the help of IPATH, including Joel Grimwood and Isabelle Carnell-Holdaway. Joel Grimwood was a patient who was ineligible for heart transplantation due to antimicrobial resistant infection. With phage and antibiotic infusions, Grimwood was able to become healthy enough to undergo a successful heart transplantation.[13] Isabelle Carnell-Holdaway was a 15-year-old patient that underwent experimental treatment in which she was the first person in the world to be administered genetically modified phages to fight a multi-drug resistant infection following lung transplantation.[14][15]

gollark: Elliptic curve cryptography.
gollark: Also, you can. (EDIT: can install Opus I mean)
gollark: <@151391317740486657> If you can find a flaw in ECC I think you could also steal bitcoin...
gollark: If you have the private key, you can generate signatures for any startup. You don't, though. The stuff written onto disks *also* has a UUID embedded (on the more complex ones), which is part of the signed bit.
gollark: The signatures are programatically generated from the contents of the file and my private key. PotatOS has the *public* key, so it can verify that the signature was generated from the corresponding private key.

References
  1. Strathdee, Steffanie. "IPATH". Center for Innovative Phage Applications and Therapeutics.
  2. "- NIH RePORTER - NIH Research Portfolio Online Reporting Tools Expenditures and Results". projectreporter.nih.gov. Retrieved 2019-05-28.
  3. Lane, Richard (21 July 2014). "Steffanie Strathdee: "called" to HIV prevention". Lancet. 385 (9962): 20. doi:10.1016/S0140-6736(14)61048-5. PMID 25059940.
  4. "TIME".
  5. Division of Global Public Health, University of California San Diego (6 April 2018). "Dr. Steffanie A. Strathdee". Division of Global Public Health UCSD. Retrieved 6 April 2018.
  6. "UCSD Global Health Institute". UC San Diego Global Health Institute.
  7. "UCSD Department of Medicine". UC San Diego Department of Medicine.
  9. JAMA and Lancet
  11. ,
  13. UC San Diego Health (2018-06-21), Turning a Phage: Innovative Therapy Clears Infection and Allows Heart Transplantion, retrieved 2019-05-16
  14. "Genetically Modified Viruses Help Save A Patient With A 'Superbug' Infection". NPR.org. Retrieved 2019-05-16.
  15. Spencer, Helen; Hatfull, Graham F.; Schooley, Robert T.; Jacobs-Sera, Deborah; Soothill, James; Kimberly C. Gilmour; Harris, Kathryn; Ford, Katrina; Russell, Daniel A. (May 2019). "Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus". Nature Medicine. 25 (5): 730–733. doi:10.1038/s41591-019-0437-z. ISSN 1546-170X. PMC 6557439. PMID 31068712.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.